The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,414.00
Bid: 12,410.00
Ask: 12,412.00
Change: 54.00 (0.44%)
Spread: 2.00 (0.016%)
Open: 12,330.00
High: 12,422.00
Low: 12,316.00
Prev. Close: 12,360.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Fears Of South Africa Variant Raise Prospect Of Autumn Booster Jab

Mon, 08th Feb 2021 06:57

(Alliance News) - Britons face needing a third jab this year amid concerns about the Oxford University and AstraZeneca PLC vaccine's effectiveness against the South African coronavirus variant.

UK Vaccines Minister Nadhim Zahawi was forced to defend the vaccine after a new study in South Africa found it was not effective at preventing mild illness caused by the more infectious mutation.

South Africa has suspended the rollout of the British-designed vaccine to healthcare staff following the results, which have yet to be peer reviewed.

Zahawi urged the public to keep faith with the Oxford jab as scientists working on the vaccine raised the prospect of having a booster dose available by the autumn.

Writing in the Daily Telegraph, the minister said: "While it is right and necessary to prepare for the deployment of an updated vaccine, we can take confidence from the current roll out and the protection it will provide all of us against this terrible disease.

"We need to be aware that even where a vaccine has reduced efficacy in preventing infection there may still be good efficacy against severe disease, hospitalisation, and death. This is vitally important for protecting the healthcare system."

It comes as:

– The number of people in the UK who have received a first dose of a vaccine passed the 12 million mark, with jabs administered at a rate of almost 1,000 per minute during a one hour period over the weekend.

– A new Scottish record for vaccines was set, with the number of initial jabs given in one day passing 50,000 for the first time.

– Migrants living in the UK unlawfully will be given an amnesty in order to get vaccinated, the Daily Mail reported.

– People living in Northern Ireland who cross the Irish border without a reasonable excuse face a 100 euro fine from Monday.

– People who have been given both doses will be able to request their vaccine record from their GP to allow them to go on holiday to countries where immunity passports are required, Zahawi confirmed.

Scientists agreed more research is required into the level of protection the Oxford vaccine affords against the South African variant but some expressed concern over the preliminary findings from the southern hemisphere.

AstraZeneca said on Sunday the fact the study into the E484K mutation involved 2,000 people who were mostly young and healthy meant it had "not been able to properly ascertain" whether it prevented against severe illness and hospital admission.

But the Anglo-Swedish pharmaceutical company said it believed "our vaccine will still protect against severe disease" as the neutralising antibody activity is "equivalent to other Covid-19 vaccines that have demonstrated activity against more severe disease".

Sarah Gilbert, the Oxford vaccine's lead researcher, said her team was working on having an adapted version of their jab that could tackle the South Africa mutation – of which cases have been found in England – "available for the autumn".

She said: "This year we expect to show that the new version of the vaccine will generate antibodies that recognise the new variant. Then it will be very much like working on flu vaccines. It looks very much like it will be available for the autumn."

Zahawi said he and Jonathan Van-Tam, England's deputy chief medical officer, agreed there was likely to be a follow-up jab programme later in the year.

"We see very much probably an annual or booster in the autumn and then an annual (jab), in the way we do with flu vaccinations where you look at what variant of virus is spreading around the world, rapidly produce a variant of vaccine and then begin to vaccinate and protect the nation," he told BBC One's Andrew Marr Show.

The government's announcement that it had secured 20 million more rapid-result coronavirus tests signalled that the prime minister – due to set out his road map for easing restrictions later this month – could be preparing to relax lockdown rules in some settings as daily Covid deaths fell to their lowest level in weeks.

Figures showed that a further 373 people had died within 28 days of testing positive for Covid-19 as of Sunday, bringing the UK total to 112,465.

The lateral flow antigen tests, which can return results in under 30 minutes, are the first British-made tests to be validated by Public Health England in the laboratory and will be deployed to test NHS and care home staff, as well as in schools, universities, and for key workers.

But Tim Spector, professor of genetic epidemiology at King's College London, said the impact of Covid was likely to be felt at large gatherings long after lockdown was over.

He told Times Radio: "I can't see us suddenly having another Cheltenham Festival with no regulations again, I can't see us having massive weddings with people coming from all over the world.

"I think for the next few years those days are gone."

By Patrick Daly, PA Political Correspondent

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 Nov 2023 11:34

AstraZeneca's Lokelma lets kidney disease patients maintain therapy

(Alliance News) - AstraZeneca PLC on Thursday celebrated results from an observational study, which showed that treating hyperkalaemia with the potassium binder, Lokelma, allows chronic kidney disease and heart failure patients to maintain RAASi therapy.

Read more
2 Nov 2023 15:57

UK earnings, trading statements calendar - next 7 days

Friday 3 November 
no events scheduled 
Monday 6 November 
Kingspan Group PLCTrading Statement
Kosmos Energy LtdQ3 Results
Ryanair Holdings PLCHalf Year Results
Tuesday 7 November 
Associated British Foods PLCFull Year Results
Beazley PLCQ3 Results
Direct Line Insurance Group PLCTrading Statement
dotdigital Group PLCFull Year Results
IWG PLCQ3 Results
Persimmon PLCTrading Statement
RS Group PLCHalf Year Results
Vaalco Energy IncQ3 Results
Watches of Switzerland Group PLCTrading Statement
Wednesday 8 November 
Conduit Holdings LtdQ3 Results
ITV PLCTrading Statement
JD Wetherspoon PLCQ1 Results
Marks & Spencer Group PLCHalf Year Results
MaxCyte IncQ3 Results
Secure Trust Bank PLCTrading Statement
Smiths News PLCFull Year Results
Time Out Group PLCFull Year Results
Thursday 9 November 
3i Group PLCHalf Year Results
Apax Global Alpha LtdQ3 Results
AstraZeneca PLCQ3 Results
Auto Trader Group PLCHalf Year Results
B&M European Value Retail SAHalf Year Results
Domino's Pizza Group PLCTrading Statement
Endeavour Mining PLCQ3 Results
Flutter Entertainment PLCTrading Statement
IMI PLCTrading Statement
Indivior PLCQ3 Results
John Wood Group PLCTrading Statement
Lancashire Holdings LtdTrading Statement
National Grid PLCHalf Year Results
Regional REIT LtdTrading Statement
Renewi PLCHalf Year Results
S4 Capital PLCTrading Statement
Tate & Lyle PLCHalf Year Results
Taylor Wimpey PLCTrading Statement
TBC Bank Group PLCQ3 Results
TheWorks.co.uk PLCTrading Statement
Trakm8 Holdings PLCHalf Year Results
Urban Logistics REIT PLCHalf Year Results
Vistry Group PLCTrading Statement
WH Smith PLCFull Year Results
Wincanton PLCHalf Year Results
Wizz Air Holdings PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
1 Nov 2023 08:59

AstraZeneca launches collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Wednesday announced a new collaboration and investment agreement with clinical-stage biotechnology company Cellectis.

Read more
1 Nov 2023 07:33

AstraZeneca invests $220m in French gene-editing group Cellectis

(Sharecast News) - AstraZeneca is to invest in French biopharma group Cellectis to use its gene-editing technologies to develop next-gen therapeutics in areas like oncology, immunology and rare diseases.

Read more
30 Oct 2023 09:40

LONDON BROKER RATINGS: Jefferies cuts NatWest to underperform from buy

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
25 Oct 2023 11:04

PRESS: Soriot commits to five more years as AstraZeneca CEO - Times

(Alliance News) - Pascal Soriot has committed to remaining as chief executive officer of AstraZeneca PLC for another five years, The Times reported on Wednesday.

Read more
24 Oct 2023 17:08

LONDON MARKET CLOSE: FTSE 100 shakes off midday losses after US data

(Alliance News) - The FTSE 100 closed in the green on Tuesday following positive private sector data out of the US, despite figures closer to home showing a weaker UK private sector and rising unemployment.

Read more
24 Oct 2023 11:06

AstraZeneca says US accepts self-administered flu vaccine for review

(Alliance News) - AstraZeneca PLC on Tuesday said the US health watchdog has approved a review for its FluMist Quadrivalent self-administered flu vaccine, for which the drugmaker is seeking a green light.

Read more
23 Oct 2023 17:50

AstraZeneca celebrates drug trial results for cancer indications

(Alliance News) - AstraZeneca PLC on Monday said new drugs, developed in partnership with Daiichi Sankyo Co Ltd, showed positive results in patients with solid tumours, lung and breast cancer.

Read more
23 Oct 2023 17:08

LONDON MARKET CLOSE: Stocks largely down on Middle East hostilities

(Alliance News) - Stock prices in London closed largely lower on Monday, as investors were unable to shake off concerns surrounding the conflict in the Middle East, while developments in the US bond market added to the drama.

Read more
23 Oct 2023 08:45

TOP NEWS: AstraZeneca says Enhertu approved by European Commission

(Alliance News) - AstraZeneca PLC on Monday said its Enhertu treatment has been approved by the European Commission to treat adult lung cancer patients.

Read more
23 Oct 2023 07:46

LONDON BRIEFING: Keller expects higher profit; Upland rejects approach

(Alliance News) - Stocks in London are set to open slightly higher on Monday, as risk sentiment improves after a difficult period for markets last week.

Read more
18 Oct 2023 09:04

AstraZeneca drug Solaris approved in China as NMOSD treatment

(Alliance News) - AstraZeneca PLC on Wednesday announced that eculizumab, whose brand name is Solaris, has been approved in China to treat patients with neuromyelitis optica spectrum disorder

Read more
17 Oct 2023 12:06

LONDON MARKET MIDDAY: European markets uneasy but FTSE 100 outperforms

(Alliance News) - London's FTSE 100 higher was higher around midday, though it was defensive stocks such as utilities and pharmaceuticals which led the charge, suggesting there is still lingering discomfort in markets amid tensions in the Middle East.

Read more
16 Oct 2023 08:34

TOP NEWS: AstraZeneca's cancer drug gets priority review from US FDA

(Alliance News) - AstraZeneca PLC on Monday said that its new drug application for Tagrisso has been granted priority review in the US, after trial results extended progression-free survival.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.